MilliporeSigma

Therapeutic use of the phosphate binder lanthanum carbonate.

Expert opinion on drug metabolism & toxicology (2009-02-25)
Amy Barton Pai, Todd A Conner, Charles R McQuade
ABSTRACT

Hyperphosphatemia is recognized as a principal mineral disorder in chronic kidney disease (CKD) that leads to the development of secondary hyperparathyroidism. Recent data indicate that hyperphosphatemia is associated with accelerated cardiac calcification and increased mortality in patients with CKD. Control of serum phosphorus is accomplished with phosphate binder therapies that include calcium and aluminum salts. Recently, calcium-based binders have undergone reevaluation because of their association with cardiac calcification. The non-calcium, non-aluminum binder sevelamer hydrochloride has been associated with slower progression of cardiac calcification in clinical trials. Lanthanum carbonate is a newer phosphate binder with phosphate binding activity similar to aluminum salts making this agent a compelling alternative; however, more data are needed to evaluate long-term safety and effects on cardiovascular end points.

MATERIALS
Product Number
Brand
Product Description

Lanthanum, foil, 50x50mm, thickness 0.1mm, as rolled, 99%
Lanthanum, foil, not light tested, 100x100mm, thickness 0.025mm, as rolled, 99%
Lanthanum, foil, not light tested, 25x25mm, thickness 0.025mm, as rolled, 99%
Lanthanum, foil, 100x100mm, thickness 0.125mm, as rolled, 99%
Lanthanum, rod, 50mm, diameter 6.35mm, cast, 99%
Lanthanum, foil, 100x100mm, thickness 0.1mm, as rolled, 99%
Lanthanum, foil, not light tested, 50x50mm, thickness 0.025mm, as rolled, 99%
Lanthanum, foil, 25x25mm, thickness 0.125mm, as rolled, 99%
Lanthanum, foil, 25x25mm, thickness 0.1mm, as rolled, 99%
Lanthanum, rod, 100mm, diameter 6.35mm, cast, 99%
Sigma-Aldrich
Lanthanum, powder, −40 mesh, under oil, 99.9% trace rare earth metals basis
Sigma-Aldrich
Lanthanum, pieces